Omega-3 Supplements Show Promise for Preventing Cognitive Decline in At-Risk Older Adults

The LO MAPT trial examined whether omega-3 supplementation could prevent cognitive decline in older adults with low DHA/EPA blood levels and Alzheimer's risk factors. This phase III randomized controlled trial represents one of the largest investigations into omega-3s for brain health prevention.

Researchers enrolled 774 participants aged 65 and older across multiple centers. All participants had low red blood cell DHA/EPA index plus either subjective memory complaints or family history of Alzheimer's disease. The study used a rigorous double-blind, placebo-controlled design with participants randomly assigned to receive either omega-3 supplements or placebo.

The intervention lasted 18 months, followed by an 18-month open-label extension where all participants could receive omega-3s. Researchers measured cognitive function, memory performance, and other neurological markers throughout the study period. The trial specifically targeted individuals with insufficient omega-3 status, recognizing that these essential fatty acids play crucial roles in brain cell membrane function and neuroinflammation.

This completed trial addresses a critical gap in longevity research by focusing on prevention rather than treatment. The results could inform evidence-based recommendations for omega-3 supplementation in cognitive health maintenance. Given the growing prevalence of Alzheimer's disease and limited treatment options, identifying effective prevention strategies through nutritional interventions represents a promising approach for healthy brain aging and extending cognitive healthspan in older adults.